NetraMark Holdings (TSE:AIAI) has released an update.
NetraMark Holdings is set to revolutionize clinical trials with its new Treatment Attitude Profile (TAP™) scale, unveiled at the ASCP Annual Meeting. The scale, powered by NetraMark’s NetraAI technology, identifies placebo responders, enhancing trial design and patient selection. This innovation promises to reduce time, cost, and failure rates in psychiatric clinical trial development, marking a significant step forward in treatment efficacy discovery.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.
